The global leadership into malnutrition criteria reveals a high percentage of malnutrition which negatively influences overall survival in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogues

#4173

Introduction: Patients (pts) with GEP-NETs treated with somatostatin analogues (SSA’s) are at risk of malnutrition. This has been reported, using weight loss or body mass index (BMI) only. The Global leadership into malnutrition (GLIM) criteria include weight loss, BMI and sarcopenia. In pts with other types of cancer the presence of malnutrition, has a negative effect on overall survival (OS). In pts with GEP-NETs treated with SSA’s this has not been explored before.

Aim(s): To describe the presence of malnutrition in pts with GEP-NETs treated with SSA’s based on the GLIM criteria and association with OS.

Materials and methods: Cross-sectional study, single-time screening pts with GEP-NETs using SSA’s using the GLIM criteria. Body composition analysis for sarcopenia were performed. OS since the date of nutrition screening was calculated until data cut-off (censor January 2023).

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,